LONDON (ShareCast) - (Sharecast News) - Alliance Pharma updated the market on its trading on Wednesday, reiterating that the year had started well, adding that it was continuing to see some "strong performances" from its key brands.
The AIM-traded firm, which was holding its annual general meeting, said integration of the Biogix business and the Amberen brand into its US-based operations was progressing "very well", with integration almost complete.

Chairman David Cook said current trading and expectations for Amberen remained in line with its pre-acquisition forecasts.

"We remain confident in our ability to weather any ongoing disruption to our business in those areas of the world which continue to be challenged by the global pandemic, and to deliver full year results in line with market expectations," Cook said.

Alliance said further commentary on its first half trading performance and full-year outlook would be provided in mid-July, in its interim trading update.

At 1008 BST, shares in Alliance Pharma were up 0.29% at 95.28p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE